Novartis Sues Sun to Block Copies of Xiidra Dry-Eye Treatment

Novartis said Sun’s proposed generic version of Xiidra infringes five patents related to the treatment for dry-eye disease.

• Novartis is seeking court order blocking copies until patents have expired and while the case proceeds, according to complaint filed Tuesday in federal court in Wilmington, Delaware
• Two patents expire in October 2030, one in November 2030, one in July 2033 and one in December 2033: supplemental filing
  • Latest-expiring patent, titled “LFA-1 Inhibitor Formulations,” was issued July 13
• Xiidra treats both signs and symptoms of dry eye by inhibiting inflammation caused by the disease
• Novartis bought Xiidra from Takeda in 2019 ...